These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Selegiline as neuroprotective therapy in Parkinson's disease: concepts and controversies. Langston JW Neurology; 1990 Oct; 40(10 Suppl 3):suppl 61-6; discussion 67-9. PubMed ID: 2120617 [No Abstract] [Full Text] [Related]
23. Potential parkinsonian protoxicants within and without. Collins MA Neurobiol Aging; 1994; 15(2):277-8. PubMed ID: 7838312 [No Abstract] [Full Text] [Related]
24. Melanin and neuromelanin binding of drugs and chemicals: toxicological implications. Karlsson O; Lindquist NG Arch Toxicol; 2016 Aug; 90(8):1883-91. PubMed ID: 27311820 [TBL] [Abstract][Full Text] [Related]
25. Reprint of: revisiting oxidative stress and mitochondrial dysfunction in the pathogenesis of Parkinson disease-resemblance to the effect of amphetamine drugs of abuse. Perfeito R; Cunha-Oliveira T; Rego AC Free Radic Biol Med; 2013 Sep; 62():186-201. PubMed ID: 23743292 [TBL] [Abstract][Full Text] [Related]
26. [Parkinsonism induced by MPTP as an experimental model of Parkinson disease: similarities and differences]. Luquin MR; Obeso JA; Herrero MT; Laguna J; Martínez-Lage JM Neurologia; 1991 Oct; 6(8):287-94. PubMed ID: 1790005 [TBL] [Abstract][Full Text] [Related]
27. [Search for the cause of Parkinson's disease]. Langston JW Arch Neurobiol (Madr); 1991; 54(6):264-71. PubMed ID: 1811457 [No Abstract] [Full Text] [Related]
28. Modeling neurodegenerative diseases in vivo review. von Bohlen Und Halbach O Neurodegener Dis; 2005; 2(6):313-20. PubMed ID: 16909014 [TBL] [Abstract][Full Text] [Related]
29. Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses? Beal MF Ann Neurol; 1992 Feb; 31(2):119-30. PubMed ID: 1349466 [TBL] [Abstract][Full Text] [Related]
30. Parkinson's disease. Marsden CD Postgrad Med J; 1992 Jul; 68(801):538-43. PubMed ID: 1437950 [No Abstract] [Full Text] [Related]
31. [Anatomo-clinical aspects of Parkinson's disease and parkinsonian syndromes]. Gainotti G Riv Neurol; 1978; 48(2):143-92. PubMed ID: 351788 [No Abstract] [Full Text] [Related]
33. MPTP effects on dopamine neurons. Kopin IJ Ann N Y Acad Sci; 1988; 537():451-61. PubMed ID: 3059935 [No Abstract] [Full Text] [Related]
34. Progression and recovery of Parkinsonism in a chronic progressive MPTP-induction model in the marmoset without persistent molecular and cellular damage. Franke SK; van Kesteren RE; Wubben JA; Hofman S; Paliukhovich I; van der Schors RC; van Nierop P; Smit AB; Philippens IH Neuroscience; 2016 Jan; 312():247-59. PubMed ID: 26431624 [TBL] [Abstract][Full Text] [Related]
35. [Experimental models of Parkinson's disease]. Féger J; Pessigliore M; François C; Tremblay L; Hirsch E Ann Pharm Fr; 2002 Jan; 60(1):3-21. PubMed ID: 11976545 [TBL] [Abstract][Full Text] [Related]
36. Targeted deletion of the aquaglyceroporin AQP9 is protective in a mouse model of Parkinson's disease. Stahl K; Rahmani S; Prydz A; Skauli N; MacAulay N; Mylonakou MN; Torp R; Skare Ø; Berg T; Leergaard TB; Paulsen RE; Ottersen OP; Amiry-Moghaddam M PLoS One; 2018; 13(3):e0194896. PubMed ID: 29566083 [TBL] [Abstract][Full Text] [Related]
37. Endogenously occurring beta-carboline induces parkinsonism in nonprimate animals: a possible causative protoxin in idiopathic Parkinson's disease. Matsubara K; Gonda T; Sawada H; Uezono T; Kobayashi Y; Kawamura T; Ohtaki K; Kimura K; Akaike A J Neurochem; 1998 Feb; 70(2):727-35. PubMed ID: 9453568 [TBL] [Abstract][Full Text] [Related]